126
|
Janert M, Weiss B, Lemmer L, Nauck MA. Psychologische Intervention in einer Diabetes-Spezialklinik: Unterschiede zwischen Patienten mit Typ 1- und Typ 2-Diabetes. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
127
|
Nauck MA, Kluge S, Pilzer J, Fehske CJ, Silbermann S, Froehlich H, Jahn E, Limberg R. Bewertung von Therapieerfolg und Kriterien für die Wahl einer Medikation add-on zu Metformin: Ergebnisse einer Erhebung bei niedergelassenen Ärzten. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
128
|
Buse J, Montanya E, Sesti G, Rosenstock J, Nauck M, Holst J, Lüthgens B. Häufigkeit und Ausmaß der Antikörperbildung sind unter Liraglutid geringer als unter Exenatid: Ergebnisse der LEAD™-6 Studie. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
129
|
Becker B, Vogtmeier S, Terhoeven L, Vardarli I, Nauck MA. Charakterisierung der Blutzucker-Einstellungsqualität unter intensivierter Insulintherapie bei Patienten mit Typ 1- und Typ 2-Diabetes. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
130
|
Kern W, Pratley R, Nauck M, Bailey T, Montanya E, Filetti S, Garber A, Davies M, Kretzschmar Y. Ein Jahr Behandlung mit Liraglutid bewirkt bei Patienten mit Typ 2 Diabetes eine nachhaltige und effektivere Blutzuckereinstellung und Gewichtsreduktion als Sitagliptin. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
131
|
Nauck M, Terhoeven L, Becker B, Vogtmeier S, Walter K, Becker K. Reproduzierbarkeit sowie Abhängigkeit vom Nüchternblutzucker der Magenentleerungsgeschwindigkeit bei Patienten mit Typ 1-Diabetes, gemessen mit wiederholten 13C-Octanoat Atem-Tests. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
132
|
Werner J, Schulze H, Nawrodt B, Janert M, Vardarli I, Nauck M. Auswirkungen eines Hundes auf körperliche Aktivität, Stoffwechseleinstellung und Gewichtskontrolle bei Typ 1- und Typ 2-Diabetes. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
133
|
Vardarli MC, Nauck MA, Hammes HP, Vardarli I. Insulinsensitivität, Betazellfunktion und Adipokine während und nach Ramadan-Fasten bei gesunden Männern. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
134
|
Friedrich N, Schneider H, Dörr M, Nauck M, Völzke H, Klotsche J, Sievers C, Pittrow D, Böhler S, Lehnert H, Pieper L, Wittchen HU, Wallaschofski H, Stalla GK. All-cause mortality and serum insulin-like growth factor I in primary care patients. Growth Horm IGF Res 2011; 21:102-106. [PMID: 21435927 DOI: 10.1016/j.ghir.2011.02.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2010] [Revised: 12/14/2010] [Accepted: 02/27/2011] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Previous population-based studies provided conflicting results regarding the association of total serum insulin-like growth factor I (IGF-I) and mortality. The aim of the present study was to assess the relation of IGF-I levels with all-cause mortality in a prospective study. DESIGN DETECT (Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment) is a large, multistage, and nationally representative study of primary care patients in Germany. The study population included 2463 men and 3603 women. Death rates were recorded by the respective primary care physician. Serum total IGF-I levels were determined by chemiluminescence immunoassays and categorized into three groups (low, moderate, and high) according to the sex- and age-specific 10th and 90th percentiles. RESULTS Adjusted analyses revealed that men with low [hazard ratio (HR) 1.70 (95% confidence interval [CI] 1.05-2.73), p=0.03] and high [HR 1.76 (95% CI 1.09-2.85), p=0.02] IGF-I levels had higher risk of all-cause mortality compared to men with moderate IGF-I levels. The specificity of low IGF-I and high IGF-I levels increased with lower and higher cut-offs, respectively. No such association became apparent in women. CONCLUSIONS The present study revealed a U-shaped relation between IGF-I and all-cause mortality in male primary care patients.
Collapse
|
135
|
Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65:397-407. [PMID: 21355967 PMCID: PMC3085127 DOI: 10.1111/j.1742-1241.2011.02656.x] [Citation(s) in RCA: 188] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
AIM The aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type 2 diabetes. METHODS In an open-label, parallel-group trial, metformin-treated participants were randomised to liraglutide 1.2 mg/day (n=225), liraglutide 1.8 mg/day (n=221) or sitagliptin 100 mg/day (n=219) for 26 weeks (main phase). Participants continued the same treatment in a 26-week extension. RESULTS Liraglutide (1.2 or 1.8 mg) was superior to sitagliptin for reducing HbA(1c) from baseline (8.4-8.5%) to 52 weeks: -1.29% and -1.51% vs. -0.88% respectively. Estimated mean treatment differences between liraglutide and sitagliptin were as follows: -0.40% (95% confidence interval -0.59 to -0.22) for 1.2 mg and -0.63% (-0.81 to -0.44) for 1.8 mg (both p<0.0001). Weight loss was greater with liraglutide 1.2 mg (-2.78 kg) and 1.8 mg (-3.68 kg) than sitagliptin (-1.16 kg) (both p<0.0001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly more with liraglutide 1.8 mg than with sitagliptin (p=0.03). Proportions of participants reporting adverse events were generally comparable; minor hypoglycaemia was 8.1%, 8.3% and 6.4% for liraglutide 1.2 mg, 1.8 mg and sitagliptin respectively. Gastrointestinal side effects, mainly nausea, initially occurred more frequently with liraglutide, but declined after several weeks. CONCLUSION Liraglutide provides greater sustained glycaemic control and body weight reduction over 52 weeks. Treatment satisfaction was significantly greater with 1.8 mg liraglutide, similar to 26-week results. The safety profiles of liraglutide and sitagliptin are consistent with previous reports.
Collapse
|
136
|
Gläser S, Ittermann T, Koch B, Völzke H, Wallaschofski H, Nauck M, Warnke C, Ewert R, Schäper C. Lungenvolumina, Atemwegsobstruktion und systemische Inflammation - Ergebnisse der Study of Health in Pomerania. Pneumologie 2011. [DOI: 10.1055/s-0031-1272023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
137
|
Nauck M. Werden DPP-4-Hemmer Sulfonylharnstoffe in der Therapie des Typ-2-Diabetes ersetzen? Pro. Dtsch Med Wochenschr 2011; 136:546. [DOI: 10.1055/s-0031-1272565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
138
|
Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54:10-8. [PMID: 20871975 DOI: 10.1007/s00125-010-1896-4] [Citation(s) in RCA: 328] [Impact Index Per Article: 25.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2010] [Accepted: 07/30/2010] [Indexed: 01/08/2023]
Abstract
The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.
Collapse
|
139
|
Haring R, Baumeister SE, Völzke H, Kohlmann T, Marschall P, Flessa S, Nauck M, Wallaschofski H. Prospective association of low serum total testosterone levels with health care utilization and costs in a population-based cohort of men. ACTA ACUST UNITED AC 2010; 33:800-9. [DOI: 10.1111/j.1365-2605.2009.01029.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
140
|
Matthaei S, Bierwirth R, Fritsche A, Gallwitz B, Häring HU, Joost HG, Kellerer M, Kloos C, Kunt T, Nauck M, Schernthaner G, Siegel E, Thienel F. Behandlung des Diabetes mellitus Typ 2. DIABETOL STOFFWECHS 2010. [DOI: 10.1055/s-0030-1262619] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
141
|
Völzke H, Schmidt CO, John U, Wallaschofski H, Dörr M, Nauck M. Reference levels for serum thyroid function tests of diagnostic and prognostic significance. Horm Metab Res 2010; 42:809-14. [PMID: 20809459 DOI: 10.1055/s-0030-1263121] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
A controversy exists on the value of upper thyrotropin (TSH) reference level. Currently available studies are based on cross-sectional data leaving uncertainty about the prognostic significance of the upper TSH reference level. With the present study we sought to establish reference values for serum thyroid function tests that are of both diagnostic and prognostic significance. We used data from the prospective population-based Study of Health in Pomerania (SHIP) with a 5 year follow-up (6080 person-years). We included data from 1203 subjects (525 women) without prevalent subclinical or manifest thyroid disorders. An event-free reference population was separated comprising 1053 subjects (473 women). When comparing reference values as analyzed from either the whole reference population or the event-free reference population, we observed notable differences in TSH reference intervals. While the lower TSH reference values were similar in both populations, the upper value was 1.95 mIU/l and thus by 7.6% lower in subjects without incident events compared to the whole reference population. Both populations did not substantially differ with respect to serum FT3 and FT4 reference intervals. The upper TSH reference value is lower than recommended when both diagnostic and prognostic significance are considered in the definition of the TSH reference range.
Collapse
|
142
|
Koch B, Glaser S, Schaper C, Krebs A, Nauck M, Dorr M, Haring R, Volzke H, Felix SB, Ewert R, Wallaschofski H, Friedrich N. Association Between Serum Testosterone and Sex Hormone-Binding Globulin and Exercise Capacity in Men: Results of the Study of Health in Pomerania (SHIP). ACTA ACUST UNITED AC 2010; 32:135-43. [DOI: 10.2164/jandrol.110.010074] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
143
|
Friedrich N, Schneider HJ, Nauck M, Wallaschofski H, Stalla GK. Improved prediction of all-cause mortality by a combination of IGF-I and total testosterone in adult men. Exp Clin Endocrinol Diabetes 2010. [DOI: 10.1055/s-0030-1267008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
144
|
Ittermann T, Baumeister S, Völzke H, Wasner C, Schminke U, Wallaschofski H, Nauck M, Lüdemann J. Are serum TSH levels associated with oxidized low density lipoprotein? DAS GESUNDHEITSWESEN 2010. [DOI: 10.1055/s-0030-1266362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
145
|
Lau K, Lorbeer R, Haring R, Schmidt C, Wallaschofski H, Nauck M, John U, Baumeister S, Völzke H. The association between fatty liver disease and blood pressure in a population-based cohort study. DAS GESUNDHEITSWESEN 2010. [DOI: 10.1055/s-0030-1266409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
146
|
Friedrich N, Nauck M, Völzke H, Brabant G, Wallaschofski H. Association between Insulin-like growth factor-I and the incidence of metabolic syndrome: Results from the Study of Health in Pomerania. DAS GESUNDHEITSWESEN 2010. [DOI: 10.1055/s-0030-1266361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
147
|
Friedrich N, Schneider H, Nauck M, Wallaschofski H, Stalla G. The combined influence of low serum Insulin-Like Growth Factor I and low total testosterone on all-cause mortality in adult men. DAS GESUNDHEITSWESEN 2010. [DOI: 10.1055/s-0030-1266471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
148
|
Völzke H, Lorbeer R, Dörr M, Kock H, Assel H, Ott K, Völker U, Hecker M, Hoffmann W, Nauck M, Zygmunt M, Felix S, Kroemer H. Greifswald Approach to Individualized Medicine (GANI_MED) – Rationale and Design. DAS GESUNDHEITSWESEN 2010. [DOI: 10.1055/s-0030-1266381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
149
|
Haring R, Wallaschofski H, Nauck M, Felix SB, Schmidt CO, Dörr M, Sauer S, Wilmking G, Völzke H. Total and cardiovascular disease mortality predicted by metabolic syndrome is inferior relative to its components. Exp Clin Endocrinol Diabetes 2010; 118:685-91. [PMID: 20625974 DOI: 10.1055/s-0030-1261876] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
OBJECTIVES This study examined the predictive role of metabolic syndrome (MetS) and its single components for total and cardiovascular disease (CVD) mortality. METHODS We analyzed data from 3,927 participants aged 20-79 years without history of CVD, recruited for the prospective population-based Study of Health in Pomerania (SHIP). During the mean 7.2 years (25 (th), 6.6; 75 (th): 8.0) of follow-up, 240 deaths (79 CVD deaths) occurred. MetS was defined by National Cholesterol Education Program Adult Treatment Panel III guidelines. The association of MetS with total and CVD mortality was analyzed by Cox proportional hazards regression models. The impact of single MetS components on survival time was compared using standardized beta coefficients from multivariable linear regression models. RESULTS Baseline MetS prevalence was 28.8%. Age- and gender-adjusted Cox models revealed that participants with MetS had an increased risk of total mortality (hazard ratio (HR) 1.41; 95% confidence interval (95% CI) 1.09-1.82) and CVD mortality (HR 1.82; 95% CI 1.22-3.13) compared to participants without MetS. Of the single MetS components, participants with increased waist circumference (WC) and glucose levels exposed highest risk of total (HR 1.49; 95% CI 1.10-2.01; HR 2.13; 95% CI 1.58-2.90, respectively) and CVD mortality (HR 2.02; 95% CI 1.13-3.61; HR 3.15; 95% CI 1.94-5.11, respectively). Increasing WC or glucose by 1 standard deviation (SD) significantly decreased age- and gender-adjusted beta coefficients for survival time by 0.09, and 0.08 SD, respectively. CONCLUSION There was no added predictive value of MetS beyond its individual components with respect to mortality risk. Attention should be redirected to the individual components, particularly visceral obesity and high glucose, to treat each abnormality appropriately.
Collapse
|
150
|
Schipf S, Alte D, Völzke H, Friedrich N, Haring R, Lohmann T, Rathmann W, Nauck M, Felix S, Hoffmann W, John U, Wallaschofski H. Prävalenz des Metabolischen Syndroms in Deutschland: Ergebnisse der Study of Health in Pomerania (SHIP). DIABETOL STOFFWECHS 2010. [DOI: 10.1055/s-0030-1247406] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|